HALE DAVID F
Insider
First SEC filing: Aug. 12, 2021 · Latest: Aug. 12, 2021
Insider at
Insider transactions
0 buys (P)
0 sells (S)
Net: $0
Price change vs current quote, split-adjusted for corporate actions since the filing — not benchmarked, not annualized, not size-weighted
| Date | Ticker | Code | Shares | Price | Value | Owned after | Δ own | A/D | vs now |
|---|---|---|---|---|---|---|---|---|---|
| Jan. 2, 2026 | DRMA | A | 2,500 | · | · | 2,500 Direct | · | Acquired | (price as of 2026-10-02) |
| Jan. 23, 2025 | DRMA | A | 78,741 | · | · | 80,957 Indirect | +3553.29% | Acquired | (price as of 2026-10-02) |
| Jan. 21, 2025 | DRMA | A | 78,741 | · | · | 78,741 Indirect | · | Acquired | (price as of 2026-10-02) |
| Jan. 13, 2025 | DRMA | A | 5,000 | · | · | 5,000 Direct | · | Acquired | (price as of 2026-10-02) |
| Jan. 4, 2024 | DRMA | A | 10,000 | · | · | 10,000 Direct | · | Acquired | (price as of 2026-10-02) |
| Oct. 6, 2022 | DRMA | A | 30,155 | · | · | 75,720 Direct | +66.18% | Acquired | (price as of 2026-10-02) |
| July 7, 2022 | DRMA | A | 26,441 | · | · | 45,565 Direct | +138.26% | Acquired | (price as of 2026-10-02) |
| April 7, 2022 | DRMA | A | 15,466 | · | · | 19,124 Direct | +422.80% | Acquired | (price as of 2026-10-02) |
| Jan. 3, 2022 | DRMA | A | 5,000 | · | · | 5,000 Direct | · | Acquired | (price as of 2026-10-02) |
| Aug. 17, 2021 | DRMA | P | 35,714 | · | · | 35,714 Indirect | · | Acquired | (price as of 2026-10-02) |
| Aug. 17, 2021 | DRMA | C | 3,048 | · | · | 3,048 Indirect | · | Acquired | (price as of 2026-10-02) |
| Aug. 17, 2021 | DRMA | C | 62,500 | · | · | 0 Indirect | -100.00% | Disposed | (price as of 2026-10-02) |
| Aug. 17, 2021 | DRMA | C | 555,622 | · | · | 0 Indirect | -100.00% | Disposed | (price as of 2026-10-02) |
| Aug. 17, 2021 | DRMA | C | 3,571,428 | · | · | 0 Indirect | -100.00% | Disposed | (price as of 2026-10-02) |
| Aug. 17, 2021 | DRMA | C | 410,000 | · | · | 0 Indirect | -100.00% | Disposed | (price as of 2026-10-02) |
| Aug. 17, 2021 | DRMA | C | 250,000 | · | · | 0 Indirect | -100.00% | Disposed | (price as of 2026-10-02) |
| Aug. 17, 2021 | DRMA | C | 302,112 | · | · | 0 Indirect | -100.00% | Disposed | (price as of 2026-10-02) |
| Aug. 17, 2021 | DRMA | P | 35,714 | · | · | 35,714 Indirect | · | Acquired | (price as of 2026-10-02) |
| Aug. 17, 2021 | DRMA | C | 27,103 | · | · | 532,925 Indirect | +5.36% | Acquired | (price as of 2026-10-02) |
| Aug. 17, 2021 | DRMA | C | 174,216 | · | · | 505,822 Indirect | +52.54% | Acquired | (price as of 2026-10-02) |
| Aug. 17, 2021 | DRMA | C | 20,000 | · | · | 331,606 Indirect | +6.42% | Acquired | (price as of 2026-10-02) |
| Aug. 17, 2021 | DRMA | C | 12,195 | · | · | 311,606 Indirect | +4.07% | Acquired | (price as of 2026-10-02) |
| Aug. 17, 2021 | DRMA | C | 44,777 | · | · | 299,411 Indirect | +17.58% | Acquired | (price as of 2026-10-02) |
P = Open-market purchase · S = Sale · A = Grant/award · M = Option exercise · G = Gift · F = Tax withholding
Insider transactions are not a recommendation; sales are often driven by liquidity or tax reasons.
Derivative holdings (Form 4 Table II) Options, RSUs and convertible securities reported on Form 4 Table II.
| Date | Ticker | Security | Underlying | Exercise price | Expiration | Shares | A/D |
|---|---|---|---|---|---|---|---|
| Jan. 2, 2026 | DRMA | Stock Option (Right to Buy) | Common Stock | $2.18 | Jan. 1, 2036 | 2,500 | Acquired |
| Jan. 21, 2025 | DRMA | Warrant (Right to Buy) | Common Stock | $1.27 | · | 78,741 | Acquired |
| Jan. 13, 2025 | DRMA | Stock Option (Right to Buy) | Common Stock | $1.38 | Jan. 12, 2035 | 5,000 | Acquired |
| Jan. 4, 2024 | DRMA | Stock Option (Right to Buy) | Common Stock | $0.61 | Jan. 3, 2034 | 10,000 | Acquired |
| Jan. 3, 2022 | DRMA | Stock Option (right to buy) | Common Stock | $1.88 | Jan. 2, 2032 | 5,000 | Acquired |
| Aug. 17, 2021 | DRMA | Warrant to Purchase Common Stock | Common Stock | $7.00 | Aug. 17, 2026 | 35,714 | Acquired |
| Aug. 17, 2021 | DRMA | Warrant to Purchase Common Stock | Common Stock | $20.50 | March 14, 2026 | 3,048 | Acquired |
| Aug. 17, 2021 | DRMA | Series 1a Warrants | Common Stock | · | March 14, 2026 | 62,500 | Disposed |
| Aug. 17, 2021 | DRMA | Series 1 Preferred Stock | Common Stock | · | · | 555,622 | Disposed |
| Aug. 17, 2021 | DRMA | Series 1c Preferred Stock | Common Stock | · | · | 3,571,428 | Disposed |
| Aug. 17, 2021 | DRMA | Series 1b Preferred Stock | Common Stock | · | · | 410,000 | Disposed |
| Aug. 17, 2021 | DRMA | Series 1a Preferred Stock | Common Stock | · | · | 250,000 | Disposed |
| Aug. 17, 2021 | DRMA | Series 1d Preferred Stock | Common Stock | · | · | 302,112 | Disposed |
Exercise/conversion price is blank when not applicable (e.g. RSUs).
Initial ownership (Form 3) 11 holdings
Securities held when first becoming an insider, per SEC Form 3.
| Date | Ticker | Security | Shares | Ownership |
|---|---|---|---|---|
| Aug. 12, 2021 | DRMA | Common Stock | 3,658 | Direct |
| Aug. 12, 2021 | DRMA | Common Stock | 12,195 | Indirect |
| Aug. 12, 2021 | DRMA | Common Stock | 254,634 | Indirect |
| Aug. 12, 2021 | DRMA | Stock Option (Right to Buy) | · | Direct |
| Aug. 12, 2021 | DRMA | Stock Option (Right to Buy) | · | Direct |
| Aug. 12, 2021 | DRMA | Series 1d Preferred Stock | · | Indirect |
| Aug. 12, 2021 | DRMA | Series 1a Preferred Stock | · | Indirect |
| Aug. 12, 2021 | DRMA | Series 1b Preferred Stock | · | Indirect |
| Aug. 12, 2021 | DRMA | Series 1c Preferred Stock | · | Indirect |
| Aug. 12, 2021 | DRMA | Series 1 Preferred Stock | · | Indirect |
| Aug. 12, 2021 | DRMA | Series 1a Warrants | · | Indirect |